Human Rabies Encephalitis Prevention and Treatment: Progress Since Pasteur's Discovery

Infectious Disorders - Drug Targets

Volumn 11, Issue 3, 2011, Pages 251-299

  Dacheux, Laurent ^a   Delmas, Olivier ^a   Bourhy, Hervé ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antiviral drugs; Encephalitis; Immunoglobulin; Lyssavirus; Milwaukee protocol; Post exposure prophylaxis; Rabies virus; Vaccine

Indexed keywords

9 (2,3 DIHYDROXYPROPYL)ADENINE; ALPHA BUNGAROTOXIN; ANTIVIRUS AGENT; CHLOROQUINE; CONCANAVALIN A; CYTARABINE; CYTOCHALASIN B; CYTOCHALASIN D; DACTINOMYCIN; EGTAZIC ACID; GANGLIOSIDE; GLYCOPROTEIN; HEPARAN SULFATE; LECTIN; METHYLAMINE; MONENSIN; NERVE CELL ADHESION MOLECULE; NEUROTROPHIN 3; NIFEDIPINE; QUININE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RIBAVIRIN; SELENAZOFURIN; SIALIDASE; TRIFLUOPERAZINE; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; URACIL ARABINOSIDE; VINBLASTINE;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; CLINICAL FEATURE; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; ENCEPHALITIS; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INJECTION SITE SWELLING; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PASSIVE IMMUNIZATION; POST EXPOSURE PROPHYLAXIS; PUBLIC HEALTH PROBLEM; RABIES; RABIES VIRUS; REVIEW; VIRUS ENTRY; VIRUS REPLICATION;

EID: 79958245956     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611795768079     Document Type: Review

References (276)

1. Hemachudha, T.; Griffin, D.E.; Giffels, J.J.; Johnson, R.T.; Moser, A.B.; Phanuphak, P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N. Engl. J. Med., 1987, 316(7), 369-374.
2. Knobel, D.L.; Cleaveland, S.; Coleman, P.G.; Fevre, E.M.; Meltzer, M.I.; Miranda, M.E.; Shaw, A.; Zinsstag, J.; Meslin, F.X. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ., 2005, 83(5), 360-368.
3. Mallewa, M.; Fooks, A.R.; Banda, D.; Chikungwa, P.; Mankhambo, L.; Molyneux, E.; Molyneux, M.E.; Solomon, T. Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg. Infect. Dis., 2007, 13(1), 136-139.
4. Ly, S.; Buchy, P.; Heng, N.Y.; Ong, S.; Chhor, N.; Bourhy, H.; Vong, S. Rabies situation in Cambodia. PLoS Negl. Trop. Dis., 2009, 3(9), e511.
5. Warrell, M.J.; Warrell, D.A. Rabies and other lyssavirus diseases. Lancet, 2004, 363(9413), 959-969.
6. Laothamatas, J.; Hemachudha, T.; Mitrabhakdi, E.; Wannakrairot, P.; Tulayadaechanont, S. MR imaging in human rabies. AJNR Am. J. Neuroradiol., 2003, 24(6), 1102-1109.
7. Mitrabhakdi, E.; Shuangshoti, S.; Wannakrairot, P.; Lewis, R.A.; Susuki, K.; Laothamatas, J.; Hemachudha, T. Difference in neuropathogenetic mechanisms in human furious and paralytic rabies. J. Neurol. Sci., 2005, 238(1-2), 3-10.
8. Rupprecht, C.E.; Hanlon, C.A.; Hemachudha, T. Rabies re-examined. Lancet Infect. Dis., 2002, 2(6), 327-343.
9. Sheikh, K.A.; Ramos-Alvarez, M.; Jackson, A.C.; Li, C.Y.; Asbury, A.K.; Griffin, J.W. Overlap of pathology in paralytic rabies and axonal Guillain-Barre syndrome. Ann. Neurol., 2005, 57(5), 768-772.
10. Laothamatas, J.; Wacharapluesadee, S.; Lumlertdacha, B.; Ampawong, S.; Tepsumethanon, V.; Shuangshoti, S.; Phumesin, P.; Asavaphatiboon, S.; Worapruekjaru, L.; Avihingsanon, Y.; Israsena, N.; Lafon, M.; Wilde, H.; Hemachudha, T. Furious and paralytic rabies of canine origin: neuroimaging with virological and cytokine studies. J. Neurovirol., 2008, 14(2), 119-129.
11. Delmas, O.; Holmes, E.C.; Talbi, C.; Larrous, F.; Dacheux, L.; Bouchier, C.; Bourhy, H. Genomic diversity and evolution of the lyssaviruses. PLoS One, 2008, 3(4), e2057.
12. Assenberg, R.; Delmas, O.; Morin, B.; Graham, S.C.; De Lamballerie, X.; Laubert, C.; Coutard, B.; Grimes, J.M.; Neyts, J.; Owens, R.J.; Brandt, B.W.; Gorbalenya, A.; Tucker, P.; Stuart, D.I.; Canard, B.; Bourhy, H. Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription. Antiviral Res., 2010, 87(2), 149-161.
13. Albertini, A.A.; Wernimont, A.K.; Muziol, T.; Ravelli, R.B.; Clapier, C.R.; Schoehn, G.; Weissenhorn, W.; Ruigrok, R.W. Crystal structure of the rabies virus nucleoprotein-RNA complex. Science, 2006, 313(5785), 360-363.
14. Ge, P.; Tsao, J.; Schein, S.; Green, T.J.; Luo, M.; Zhou, Z.H. Cryo-EM model of the bullet-shaped vesicular stomatitis virus. Science, 2010, 327(5966), 689-693.
15. Graham, S.C.; Assenberg, R.; Delmas, O.; Verma, A.; Gholami, A.; Talbi, C.; Owens, R.J.; Stuart, D.I.; Grimes, J.M.; Bourhy, H. Rhabdovirus matrix protein structures reveal a novel mode of self-association. PLoS Pathog., 2008, 4(12), e1000251.
16. Roche, S.; Rey, F.A.; Gaudin, Y.; Bressanelli, S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science, 2007, 315(5813), 843-848.
17. Lentz, T.L.; Burrage, T.G.; Smith, A.L.; Crick, J.; Tignor, G.H. Is the acetylcholine receptor a rabies virus receptor? Science, 1982, 215(4529), 182-184.
18. Thoulouze, M.I.; Lafage, M.; Schachner, M.; Hartmann, U.; Cremer, H.; Lafon, M. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol., 1998, 72(9), 7181-7190.
19. Tuffereau, C.; Benejean, J.; Blondel, D.; Kieffer, B.; Flamand, A. Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J., 1998, 17(24), 7250-7259.
20. Superti, F.; Derer, M.; Tsiang, H. Mechanism of rabies virus entry into CER cells. J. Gen. Virol., 1984, 65 (Pt 4), 781-789.
21. Superti, F.; Hauttecoeur, B.; Morelec, M.J.; Goldoni, P.; Bizzini, B.; Tsiang, H. Involvement of gangliosides in rabies virus infection. J. Gen. Virol., 1986, 67 (Pt 1), 47-56.
22. Superti, F.; Seganti, L.; Tsiang, H.; Orsi, N. Role of phospholipids in rhabdovirus attachment to CER cells. Brief report. Arch. Virol., 1984, 81(3-4), 321-328.
23. Conti, C.; Tsiang, H. Effect of concanavalin A on the early events of rabies virus infection of CER cells. Intervirology, 1985, 24(3), 166-169.
24. International Committee on Taxonomy of Viruses (ICTV). Virology Division-IUMS. http://www.ictvonline.org/index.asp?bhcp=1. (Accessed October 4, 2010).
25. Dacheux, L.; Berthet, N.; Dissard, G.; Holmes, E.C.; Delmas, O.; Larrous, F.; Guigon, G.; Dickinson, P.; Faye, O.; Sall, A.A.; Old, I.G.; Kong, K.; Kennedy, G.C.; Manuguerra, J.C.; Cole, S.T.; Caro, V.; Gessain, A.; Bourhy, H. Application of broad-spectrum resequencing microarray for genotyping rhabdoviruses. J. Virol., 2010, 84(18), 9557-9574.
26. Bourhy, H.; Cowley, J.A.; Larrous, F.; Holmes, E.C.; Walker, P.J. Phylogenetic relationships among rhabdoviruses inferred using the L polymerase gene. J. Gen. Virol., 2005, 86(Pt 10), 2849-2858.
27. Kuzmin, I.V.; Hughes, G.J.; Rupprecht, C.E. Phylogenetic relationships of seven previously unclassified viruses within the family Rhabdoviridae using partial nucleoprotein gene sequences. J. Gen. Virol., 2006, 87(Pt 8), 2323-2331.
28. Kissi, B.; Tordo, N.; Bourhy, H. Genetic polymorphism in the rabies virus nucleoprotein gene. Virology, 1995, 209(2), 526-537.
29. Botvinkin, A.D.; Poleschuk, E.M.; Kuzmin, I.V.; Borisova, T.I.; Gazaryan, S.V.; Yager, P.; Rupprecht, C.E. Novel lyssaviruses isolated from bats in Russia. Emerg. Infect. Dis., 2003, 9(12), 1623-1625.
30. Kuzmin, I.V.; Orciari, L.A.; Arai, Y.T.; Smith, J.S.; Hanlon, C.A.; Kameoka, Y.; Rupprecht, C.E. Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences. Virus Res., 2003, 97(2), 65-79.
31. Leonova, G.N.; Belikov, S.I.; Kondratov, I.G.; Krylova, N.V.; Pavlenko, E.V.; Romanova, E.V.; Chentsova, I.V.; Petukhova, S.A. A fatal case of bat lyssavirus infection in Primorye Territory of the Russian Far East. Rabies Bull. Europe, 2009, 33(4), 5-8.
32. Kuzmin, I.V.; Mayer, A.E.; Niezgoda, M.; Markotter, W.; Agwanda, B.; Breiman, R.F.; Rupprecht, C.E. Shimoni bat virus, a new representative of the Lyssavirus genus. Virus Res., 2010, 149(2), 197-210.
33. Nel, L.H.; Markotter, W. Lyssaviruses. Crit. Rev. Microbiol., 2007, 33(4), 301-324.
34. Bourhy, H.; Reynes, J.M.; Dunham, E.J.; Dacheux, L.; Larrous, F.; Huong, V.T.; Xu, G.; Yan, J.; Miranda, M.E.; Holmes, E.C. The origin and phylogeography of dog rabies virus. J. Gen. Virol., 2008, 89(Pt 11), 2673-2681.
35. Nel, L.H.; Rupprecht, C.E. Emergence of lyssaviruses in the Old World: the case of Africa. Curr. Top. Microbiol. Immunol., 2007, 315, 161-193.
36. Davis, P.L.; Bourhy, H.; Holmes, E.C. The evolutionary history and dynamics of bat rabies virus. Infect. Genet. Evol., 2006, 6(6), 464-473.
37. Warrilow, D. Australian bat lyssavirus: a recently discovered new rhabdovirus. Curr. Top. Microbiol. Immunol., 2005, 292, 25-44.
38. Lumlertdacha, B.; Boongird, K.; Wanghongsa, S.; Wacharapluesadee, S.; Chanhome, L.; Khawplod, P.; Hemachudha, T.; Kuzmin, I.; Rupprecht, C.E. Survey for bat lyssaviruses, Thailand. Emerg. Infect. Dis., 2005, 11(2), 232-236.
39. Badrane, H.; Tordo, N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J. Virol., 2001, 75(17), 8096-8104.
40. Dacheux, L.; Larrous, F.; Mailles, A.; Boisseleau, D.; Delmas, O.; Biron, C.; Bouchier, C.; Capek, I.; Muller, M.; Ilari, F.; Lefranc, T.; Raffi, F.; Goudal, M.; Bourhy, H. European bat Lyssavirus transmission among cats, Europe. Emerg. Infect. Dis., 2009, 15(2), 280-284.
41. Bourhy, H.; Dacheux, L.; Strady, C.; Mailles, A. Rabies in Europe in 2005. Euro. Surveill, 2005, 10(11), 213-216.
42. De Benedictis, P.; Gallo, T.; Iob, A.; Coassin, R.; Squecco, G.; Ferri, G.; D'Ancona, F.; Marangon, S.; Capua, I.; Mutinelli, F. Emergence of fox rabies in north-eastern Italy. Euro. Surveill, 2008, 13(45), pii: 19033.
43. Hemachudha, T.; Laothamatas, J.; Rupprecht, C.E. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol., 2002, 1(2), 101-109.
44. Jackson, A. In Rabies; 2nd ed.; Jackson, A.; Wunner, W.H., Eds. Academic Press: New York, 2007; pp 341-381.
45. Constantine, D.G. Rabies transmission by nonbite route. Public Health Rep., 1962, 77, 287-9.
46. Winkler, W.G.; Fashinell, T.R.; Leffingwell, L.; Howard, P.; Conomy, P. Airborne rabies transmission in a laboratory worker. JAMA, 1973, 226(10), 1219-1221.
47. CDC Rabies in a laboratory worker--New York. MMWR Morb. Mortal. Wkly Rep., 1977, 26, 183-184.
48. Wertheim, H.F.; Nguyen, T.Q.; Nguyen, K.A.; de Jong, M.D.; Taylor, W.R.; Le, T.V.; Nguyen, H.H.; Nguyen, H.T.; Farrar, J.; Horby, P.; Nguyen, H.D. Furious rabies after an atypical exposure. PLoS Med., 2009, 6(3), e44.
49. Houff, S.A.; Burton, R.C.; Wilson, R.W.; Henson, T.E.; London, W.T.; Baer, G.M.; Anderson, L.J.; Winkler, W.G.; Madden, D.L.; Sever, J.L. Human-to-human transmission of rabies virus by corneal transplant. N. Engl. J. Med., 1979, 300(11), 603-604.
50. Maier, T.; Schwarting, A.; Mauer, D.; Ross, R.S.; Martens, A.; Kliem, V.; Wahl, J.; Panning, M.; Baumgarte, S.; Muller, T.; Pfefferle, S.; Ebel, H.; Schmidt, J.; Tenner-Racz, K.; Racz, P.; Schmid, M.; Struber, M.; Wolters, B.; Gotthardt, D.; Bitz, F.; Frisch, L.; Pfeiffer, N.; Fickenscher, H.; Sauer, P.; Rupprecht, C.E.; Roggendorf, M.; Haverich, A.; Galle, P.; Hoyer, J.; Drosten, C. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin. Infect. Dis., 2010, 50(8), 1112-1119.
51. Srinivasan, A.; Burton, E.C.; Kuehnert, M.J.; Rupprecht, C.; Sutker, W.L.; Ksiazek, T.G.; Paddock, C.D.; Guarner, J.; Shieh, W.J.; Goldsmith, C.; Hanlon, C.A.; Zoretic, J.; Fischbach, B.; Niezgoda, M.; El-Feky, W.H.; Orciari, L.; Sanchez, E.Q.; Likos, A.; Klintmalm, G.B.; Cardo, D.; LeDuc, J.; Chamberland, M.E.; Jernigan, D.B.; Zaki, S.R. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl. J. Med., 2005, 352(11), 1103-1111.
52. Iehle, C.; Dacheux, L.; Ralandison, S.; Rakoto Andrianarivelo, M.; Rousset, D.; Bourhy, H. Delivery and follow-up of a healthy newborn from a mother with clinical rabies. J. Clin. Virol., 2008, 42(1), 82-85.
53. Charlton, K.M.; Nadin-Davis, S.; Casey, G.A.; Wandeler, A.I. The long incubation period in rabies: delayed progression of infection in muscle at the site of exposure. Acta Neuropathol., 1997, 94(1), 73-77.
54. Morimoto, K.; Patel, M.; Corisdeo, S.; Hooper, D.C.; Fu, Z.F.; Rupprecht, C.E.; Koprowski, H.; Dietzschold, B. Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America. Proc. Natl. Acad. Sci. USA, 1996, 93(11), 5653-5658.
55. Hemachudha, T.; Phuapradit, P. Rabies. Curr. Opin. Neurol., 1997, 10(3), 260-267.
56. Tsiang, H. Pathophysiology of rabies virus infection of the nervous system. Adv. Virus Res., 1993, 42, 375-412.
57. Raux, H.; Flamand, A.; Blondel, D. Interaction of the rabies virus P protein with the LC8 dynein light chain. J. Virol., 2000, 74(21), 10212-10216.
58. Jacob, Y.; Badrane, H.; Ceccaldi, P.E.; Tordo, N. Cytoplasmic dynein LC8 interacts with lyssavirus phosphoprotein. J. Virol., 2000, 74(21), 10217-10222.
59. Wong, L.F.; Azzouz, M.; Walmsley, L.E.; Askham, Z.; Wilkes, F.J.; Mitrophanous, K.A.; Kingsman, S.M.; Mazarakis, N.D. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther., 2004, 9(1), 101-111.
60. Etessami, R.; Conzelmann, K.K.; Fadai-Ghotbi, B.; Natelson, B.; Tsiang, H.; Ceccaldi, P.E. Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo study. J. Gen. Virol., 2000, 81(Pt 9), 2147-2153.
61. Tirawatnpong, S.; Hemachudha, T.; Manutsathit, S.; Shuangshoti, S.; Phanthumchinda, K.; Phanuphak, P. Regional distribution of rabies viral antigen in central nervous system of human encephalitic and paralytic rabies. J. Neurol. Sci., 1989, 92(1), 91-99.
62. Murphy, F.A.; Harrison, A.K.; Winn, W.C.; Bauer, S.P. Comparative pathogenesis of rabies and rabies-like viruses: infection of the central nervous system and centrifugal spread of virus to peripheral tissues. Lab. Invest., 1973, 29(1), 1-16.
63. Jackson, A.C.; Ye, H.; Phelan, C.C.; Ridaura-Sanz, C.; Zheng, Q.; Li, Z.; Wan, X.; Lopez-Corella, E. Extraneural organ involvement in human rabies. Lab. Invest., 1999, 79(8), 945-951.
64. Hemachudha, T.; Wacharapluesadee, S.; Laothamatas, J.; Wilde, H. Rabies. Curr. Neurol. Neurosci. Rep., 2006, 6(6), 460-468.
65. Jackson, A. In Rabies; 2nd ed.; Jackson, A.; Wunner, W.H., Eds. Academic Press: New York, 2007; pp 309-340.
66. Dacheux, L.; Reynes, J.M.; Buchy, P.; Sivuth, O.; Diop, B.M.; Rousset, D.; Rathat, C.; Jolly, N.; Dufourcq, J.B.; Nareth, C.; Diop, S.; Iehle, C.; Rajerison, R.; Sadorge, C.; Bourhy, H. A reliable diagnosis of human rabies based on analysis of skin biopsy specimens. Clin. Infect. Dis., 2008, 47(11), 1410-1417.
67. Warrell, D.A. The clinical picture of rabies in man. Trans. R. Soc. Trop. Med. Hyg., 1976, 70(3), 188-195.
68. WHO. WHO Expert Consultation on Rabies - First report, World Health Organization: Geneva, Switzerland, 2005.
69. rd ed.; Kaplan, M.M.; Kowprowski, H., Eds. World Health Organization: Geneva, 1973; pp 73-84.
70. Xu, G.; Weber, P.; Hu, Q.; Xue, H.; Audry, L.; Li, C.; Wu, J.; Bourhy, H. A simple sandwich ELISA (WELYSSA) for the detection of lyssavirus nucleocapsid in rabies suspected specimens using mouse monoclonal antibodies. Biologicals, 2007, 35(4), 297-302.
71. Bourhy, H.; Rollin, P.E.; Vincent, J.; Sureau, P. Comparative field evaluation of the fluorescent-antibody test, virus isolation from tissue culture, and enzyme immunodiagnosis for rapid laboratory diagnosis of rabies. J. Clin. Microbiol., 1989, 27(3), 519-523.
72. Lembo, T.; Niezgoda, M.; Velasco-Villa, A.; Cleaveland, S.; Ernest, E.; Rupprecht, C.E. Evaluation of a direct, rapid immunohistochemical test for rabies diagnosis. Emerg. Infect. Dis., 2006, 12(2), 310-313.
73. Kang, B.; Oh, J.; Lee, C.; Park, B.K.; Park, Y.; Hong, K.; Lee, K.; Cho, B.; Song, D. Evaluation of a rapid immunodiagnostic test kit for rabies virus. J. Virol. Methods, 2007, 145(1), 30-36.
74. Sureau, P. [Rapid technics for the laboratory diagnosis of rabies]. Arch. Inst. Pasteur Tunis., 1986, 63(1), 183-197.
75. Dacheux, L.; Wacharapluesadee, S.; Hemachudha, T.; Meslin, F.X.; Buchy, P.; Reynes, J.M.; Bourhy, H. More accurate insight into the incidence of human rabies in developing countries through validated laboratory techniques. PLoS Negl. Trop. Dis., 2010, 4(11), e765.
76. nd ed.; Jackson, A.; Wunner, W.H., Eds. Academic Press: New York, 2007; pp 411-469.
77. Wacharapluesadee, S.; Hemachudha, T. Ante- and post-mortem diagnosis of rabies using nucleic acid-amplification tests. Expert Rev. Mol. Diagn., 2010, 10(2), 207-218.
78. Smith, J.S.; Yager, P.A.; Baer, G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull. World Health Organ., 1973, 48(5), 535-541.
79. Cliquet, F.; Aubert, M.; Sagne, L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods, 1998, 212(1), 79-87.
80. Feyssaguet, M.; Dacheux, L.; Audry, L.; Compoint, A.; Morize, J.L.; Blanchard, I.; Bourhy, H. Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. Vaccine, 2007, 25(12), 2244-2251.
81. Welch, R.J.; Anderson, B.L.; Litwin, C.M. An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies. J. Med. Microbiol., 2009, 58(Pt 6), 806-810.
82. Muhamuda, K.; Madhusudana, S.N.; Ravi, V. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans. Int. J. Infect. Dis., 2007, 11(5), 441-445.
83. Pasteur, L. Sur une maladie nouvelle provoquée par la salive d'un enfant mort de la rage. C R Acad. Sci., 1881, 92, 1259-1260.
84. Pasteur, L. Sur la rage. C R Acad. Sci., 1881, 92, 1259.
85. Pasteur, L.; Chamberland, C.F.; Roux, E. Nouveaux faits pour servir à la connaissance de la rage. C.R. Acad. Sci., 1882, 95, 1187.
86. Pasteur, L. Méthode pour prévenir la rage après morsure. C.R.Acad. Sci., 1885, 101, 765-774.
87. nd ed.; Baer, G.M., Ed. CRC Press: Bocar Raton, 1991; pp 571-595.
88. Debré, P. Louis Pasteur, Flammarion: 1994.
89. Geison, G.L. The private science of Louis Pasteur, Princetown University Press: Princetown, 1995.
90. Pottevin, H. Les vaccinations antirabiques à l'Institut Pasteur en 1897. Ann. Inst. Pasteur. Paris, 1898, 12, 301.
91. st century. Hybrid Hybridomics, 2002, 21(2), 123-127.
92. Javier, R.S.; Kunishita, T.; Koike, F.; Tabira, T. Semple rabies vaccine: presence of myelin basic protein and proteolipid protein and its activity in experimental allergic encephalomyelitis. J. Neurol. Sci., 1989, 93(2-3), 221-230.
93. WHO. Rabies vaccine. WHO position paper. Wkly Epidemiol. Rec., 2010, 32(85), 309-320.
94. Culbertson, C.G.; Peck, F.B., Jr.; Powell, H.M. Duck-embryo rabies vaccine; study of fixed virus vaccine grown in embryonated duck eggs and killed with beta-propiolactone (BPL). J. Am. Med. Assoc., 1956, 162(15), 1373-1376.
95. Hayflick, L. The establishment of a line (WISH) of human amnion cells in continuous cultivation. Exp. Cell Res., 1961, 23, 14-20.
96. Plotkin, S.A. Vaccine production in human diploid cell strains. Am. J. Epidemiol., 1971, 94(4), 303-306.
97. Wiktor, T.J.; Plotkin, S.A.; Koprowski, H. Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin. Dev. Biol. Stand, 1978, 40, 3-9.
98. Plotkin, S.A. Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev. Infect. Dis., 1980, 2(3), 433-448.
99. Nicholson, K.G.; Farrow, P.R.; Bijok, U.; Barth, R. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. Vaccine, 1987, 5(3), 208-210.
100. Dreesen, D.W.; Fishbein, D.B.; Kemp, D.T.; Brown, J. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine, 1989, 7(5), 397-400.
101. Berlin, B.S.; Mitchell, J.R.; Burgoyne, G.H.; Brown, W.E.; Goswick, C. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine. II. Results of clinical studies simulating prophylactic therapy for rabies exposure. JAMA, 1983, 249(19), 2663-2665.
102. Burgoyne, G.H.; Kajiya, K.D.; Brown, D.W.; Mitchell, J.R. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J. Infect. Dis., 1985, 152(1), 204-210.
103. Montagnon, B.J. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev. Biol. Stand, 1989, 70, 27-47.
104. Ajjan, N.; Pilet, C. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine, 1989, 7(2), 125-128.
105. Bourhy, H.; Goudal, M.; Mailles, A.; Sadkowska-Todys, M.; Dacheux, L.; Zeller, H. Is there a need for anti-rabies vaccine and immunoglobulins rationing in Europe? Euro. Surveill, 2009, 14(13). pii: 19166.
106. Dodet, B.; Adjogoua, E.V.; Aguemon, A.R.; Amadou, O.H.; Atipo, A.L.; Baba, B.A.; Ada, S.B.; Boumandouki, P.; Bourhy, H.; Diallo, M.K.; Diarra, L.; Diop, B.M.; Diop, S.A.; Fesriry, B.; Gosseye, S.; Hassar, M.; Kinge, T.; Kombila Nzamba, T.E.; Yandoko, E.N.; Nzengue, E.; Ramahefalalao, E.F.; Ratsitorahina, M.; Simpore, L.; Soufi, A.; Tejiokem, M.; Thiombano, R.; Tiembre, I.; Traore, A.K.; Wateba, M.I. Fighting rabies in Africa: the Africa Rabies Expert Bureau (AfroREB). Vaccine, 2008, 26(50), 6295-6298.
107. Dodet, B.; Goswami, A.; Gunasekera, A.; de Guzman, F.; Jamali, S.; Montalban, C.; Purba, W.; Quiambao, B.; Salahuddin, N.; Sampath, G.; Tang, Q.; Tantawichien, T.; Wimalaratne, O.; Ziauddin, A. Rabies awareness in eight Asian countries. Vaccine, 2008, 26(50), 6344-6348.
108. Wilde, H. Failures of post-exposure rabies prophylaxis. Vaccine, 2007, 25(44), 7605-7609.
109. Dodet, B.; African Rabies Bureau (AfroREB). The fight against rabies in Africa: From recognition to action. Vaccine, 2009, 27(37), 5027-5032.
110. Kamoltham, T.; Khawplod, P.; Wilde, H. Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. Vaccine, 2002, 20(27-28), 3272-3276.
111. Quiambao, B.P.; Dimaano, E.M.; Ambas, C.; Davis, R.; Banzhoff, A.; Malerczyk, C. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine, 2005, 23(14), 1709-1714.
112. Lang, J.; Attanath, P.; Quiambao, B.; Singhasivanon, V.; Chanthavanich, P.; Montalban, C.; Lutsch, C.; Pepin-Covatta, S.; Le Mener, V.; Miranda, M.; Sabchareon, A. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop., 1998, 70(3), 317-333.
113. Suwansrinon, K.; Jaijaroensup, W.; Daviratanasilpa, S.; Sriaroon, C.; Wilde, H.; Sitprija, V. Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine, 2005, 23(11), 1324-1325.
114. Wilde, H.; Chomchey, P.; Prakongsri, S.; Puyaratabandhu, P.; Chutivongse, S. Adverse effects of equine rabies immune gobulin. Vaccine, 1989, 7(1), 10-11.
115. Wilde, H.; Chomchey, P.; Punyaratabandhu, P.; Phanupak, P.; Chutivongse, S. Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull. World Health Organ., 1989, 67(6), 731-736.
116. Wilde, H.; Chutivongse, S. Equine rabies immune globulin: a product with an undeserved poor reputation. Am. J. Trop. Med. Hyg., 1990, 42(2), 175-178.
117. Tordo, N.; Badrane, H.; Bourhy, H.; Sacramento, D. Molecular epidemiology of lyssaviruses: focus on the glycoprotein and pseudogenes. Onderstepoort J. Vet. Res., 1993, 60(4), 315-323.
118. Fu, Z.F. Rabies and rabies research: past, present and future. Vaccine, 1997, 15 (Suppl), S20-S24.
119. McGarvey, P.B.; Hammond, J.; Dienelt, M.M.; Hooper, D.C.; Fu, Z.F.; Dietzschold, B.; Koprowski, H.; Michaels, F.H. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (N Y), 1995, 13(13), 1484-1487.
120. Modelska, A.; Dietzschold, B.; Sleysh, N.; Fu, Z.F.; Steplewski, K.; Hooper, D.C.; Koprowski, H.; Yusibov, V. Immunization against rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA, 1998, 95(5), 2481-2485.
121. Yusibov, V.; Modelska, A.; Steplewski, K.; Agadjanyan, M.; Weiner, D.; Hooper, D.C.; Koprowski, H. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl. Acad. Sci. USA, 1997, 94(11), 5784-5788.
122. Cadoz, M.; Strady, A.; Meignier, B.; Taylor, J.; Tartaglia, J.; Paoletti, E.; Plotkin, S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet, 1992, 339(8807), 1429-1432.
123. Tims, T.; Briggs, D.J.; Davis, R.D.; Moore, S.M.; Xiang, Z.; Ertl, H.C.; Fu, Z.F. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine, 2000, 18(25), 2804-2807.
124. Lodmell, D.L.; Ray, N.B.; Ewalt, L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine, 1998, 16(2-3), 115-118.
125. Lodmell, D.L.; Ray, N.B.; Parnell, M.J.; Ewalt, L.C.; Hanlon, C.A.; Shaddock, J.H.; Sanderlin, D.S.; Rupprecht, C.E. DNA immunization protects nonhuman primates against rabies virus. Nat. Med., 1998, 4(8), 949-952.
126. Perrin, P.; Jacob, Y.; Aguilar-Setien, A.; Loza-Rubio, E.; Jallet, C.; Desmezieres, E.; Aubert, M.; Cliquet, F.; Tordo, N. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine, 1999, 18(5-6), 479-486.
127. Xiang, Z.Q.; Spitalnik, S.; Tran, M.; Wunner, W.H.; Cheng, J.; Ertl, H.C. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology, 1994, 199(1), 132-140.
128. Xiang, Z.Q.; Spitalnik, S.L.; Cheng, J.; Erikson, J.; Wojczyk, B.; Ertl, H.C. Immune responses to nucleic acid vaccines to rabies virus. Virology, 1995, 209(2), 569-579.
129. Bakker, A.B.; Marissen, W.E.; Kramer, R.A.; Rice, A.B.; Weldon, W.C.; Niezgoda, M.; Hanlon, C.A.; Thijsse, S.; Backus, H.H.; de Kruif, J.; Dietzschold, B.; Rupprecht, C.E.; Goudsmit, J. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol., 2005, 79(14), 9062-9068.
130. Bakker, A.B.; Python, C.; Kissling, C.J.; Pandya, P.; Marissen, W.E.; Brink, M.F.; Lagerwerf, F.; Worst, S.; van Corven, E.; Kostense, S.; Hartmann, K.; Weverling, G.J.; Uytdehaag, F.; Herzog, C.; Briggs, D.J.; Rupprecht, C.E.; Grimaldi, R.; Goudsmit, J. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine, 2008, 26(47), 5922-5927.
131. Champion, J.M.; Kean, R.B.; Rupprecht, C.E.; Notkins, A.L.; Koprowski, H.; Dietzschold, B.; Hooper, D.C. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J. Immunol. Methods, 2000, 235(1-2), 81-90.
132. Dorfman, N.; Dietzschold, B.; Kajiyama, W.; Fu, Z.F.; Koprowski, H.; Notkins, A.L. Development of human monoclonal antibodies to rabies. Hybridoma, 1994, 13(5), 397-402.
133. Sloan, S.E.; Hanlon, C.; Weldon, W.; Niezgoda, M.; Blanton, J.; Self, J.; Rowley, K.J.; Mandell, R.B.; Babcock, G.J.; Thomas, W.D., Jr.; Rupprecht, C.E.; Ambrosino, D.M. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine, 2007, 25(15), 2800-2810.
134. Baer, G.M.; Shaddock, J.H.; Williams, L.W. Prolonging morbidity in rabid dogs by intrathecal injection of attenuated rabies vaccine. Infect. Immun., 1975, 12(1), 98-103.
135. Faber, M.; Li, J.; Kean, R.B.; Hooper, D.C.; Alugupalli, K.R.; Dietzschold, B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl. Acad. Sci. USA, 2009, 106(27), 11300-11305.
136. Warrell, M.J.; Ward, G.S.; Elwell, M.R.; Tingpalapong, M. An attempt to treat rabies encephalitis in monkeys with intrathecal live rabies virus RV 675. Brief report. Arch. Virol., 1987, 96(3-4), 271-273.
137. McGettigan, J.P. Experimental rabies vaccines for humans. Expert Rev. Vaccines, 2010, 9(10), 1177-1186.
138. Tsiang, H.; de la Porte, S.; Ambroise, D.J.; Derer, M.; Koenig, J. Infection of cultured rat myotubes and neurons from the spinal cord by rabies virus. J. Neuropathol. Exp. Neurol., 1986, 45(1), 28-42.
139. Lentz, T.L.; Fu, Y.; Lewis, P. Rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochemical and other agents. Antiviral Res., 1997, 35(1), 29-39.
140. Reagan, K.J.; Wunner, W.H. Rabies virus interaction with various cell lines is independent of the acetylcholine receptor. Arch. Virol., 1985, 84(3-4), 277-282.
141. Briggs, D.J.; Phillips, R.M. The effect of neurotoxin on rabies virus binding to mouse neuroblastoma cells. Acta Virol., 1991, 35(4), 396-399.
142. Lentz, T.L.; Wilson, P.T.; Hawrot, E.; Speicher, D.W. Amino acid sequence similarity between rabies virus glycoprotein and snake venom curaremimetic neurotoxins. Science, 1984, 226(4676), 847-848.
143. Lentz, T.L.; Hawrot, E.; Donnelly-Roberts, D.; Wilson, P.T. Synthetic peptides in the study of the interaction of rabies virus and the acetylcholine receptor. Adv. Biochem. Psychopharmacol., 1988, 44, 57-71.
144. Bracci, L.; Antoni, G.; Cusi, M.G.; Lozzi, L.; Niccolai, N.; Petreni, S.; Rustici, M.; Santucci, A.; Soldani, P.; Valensin, P.E.; et al. Antipeptide monoclonal antibodies inhibit the binding of rabies virus glycoprotein and alpha-bungarotoxin to the nicotinic acetylcholine receptor. Mol. Immunol., 1988, 25(9), 881-888.
145. Jackson, A.C.; Park, H. Experimental rabies virus infection of p75 neurotrophin receptor-deficient mice. Acta Neuropathol., 1999, 98(6), 641-644.
146. Castellanos, J.E.; Martinez-Gutierrez, M.; Hurtado, H.; Kassis, R.; Bourhy, H.; Acosta, O.; Lafon, M. Studying neurotrophin antiviral effect on rabies-infected dorsal root ganglia cultures. J. Neurovirol., 2005, 11(4), 403-410.
147. Marchetti, M.; Mastromarino, P.; Rieti, S.; Seganti, L.; Orsi, N. Inhibition of herpes simplex, rabies and rubella viruses by lectins with different specificities. Res. Virol., 1995, 146(3), 211-215.
148. Defendi, V.; Wiktor, T. In: Metabolic and Autoradiographic Studies of Rabies Virus-Infected Cells, Intern. Symp. Rabies, Tailloires, 1966; Karger, B., Ed. Tailloires, 1965; pp 119-124.
149. Hamparian, V.V.; Hilleman, M.R.; Ketler, A. Contributions to characterization and classification of animal viruses. Proc. Soc. Exp. Biol. Med., 1963, 112, 1040-1050.
150. Kissling, R.E.; Reese, D.R. Anti-Rabies Vaccine of Tissue Culture Origin. J. Immunol., 1963, 91, 362-368.
151. Enright, J.B.; Peoples, S.A.; Frye, F.L.; Franti, C.E.; Behymer, D.E. Experimental rabies chemotherapy in mice. Am. J. Vet. Res., 1971, 32(3), 437-444.
152. Flamand, A.; Pese, D.; Bussereau, F. Effect of actinomycin D and cytosine arabinoside on rabies and VSV multiplication. Virology, 1977, 78(1), 323-327.
153. Maes, R.F.; Kaplan, M.M.; Wiktor, T.; Campbell, J.B.; Koprowski, H. In: The Molecular Biology of Viruses; Colter, J.S.; Paranchych, W., Eds. Academic Press: New-York, 1967; pp 449-462.
154. Campbell, J.B.; Maes, R.F.; Wiktor, T.J.; Koprowski, H. The inhibition of rabies virus by arabinosyl cytosine. Studies on the mechanism and specificity of action. Virology, 1968, 34(4), 701-708.
155. Harmon, M.W.; Janis, B. Effects of cytosine arabinoside, adenine arabinoside, and 6-azauridine on rabies virus in vitro and in vivo. J. Infect. Dis., 1976, 133(1), 7-13.
156. Sodja, I. Experimental chemotherapy of rabies. Preliminary results. Acta Virol., 1986, 30(1), 63-68.
157. De Clercq, E.; Bergstrom, D.E.; Holy, A.; Montgomery, J.A. Broad-spectrum antiviral activity of adenosine analogues. Antiviral Res., 1984, 4(3), 119-133.
158. Bussereau, F.; Ermine, A. Effect of heteropolyanions and nucleoside analogues on rabies virus. Ann. Virologie, 1983, 134E, 487-506.
159. Bussereau, F.; Chermann, J.C.; De Clercq, E.; Hannoun, C. Search for compounds which have an inhibitory effect on rhabdovirus multiplication in vitro. Ann. Virologie, 1983, 134E, 127-134.
160. Sodja, I.; Holy, A. Effect of 9-(S)-(2,3-dihydroxypropyl)adenine on experimental rabies infection in laboratory mice. Acta Virol., 1980, 24(5), 317-324.
161. Bussereau, F.; Picard, M.; Blancou, J.; Sureau, P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol., 1988, 32(1), 33-49.
162. Yamamoto, K.; Kitano, T.; Arai, Y.T.; Yoshii, K.; Hasobe, M.; Saneyoshi, M. Inhibitory effect of a new antibiotic, guanine 7-N-oxide, on the replication of several RNA viruses. Antiviral Res., 1990, 14(3), 173-178.
163. Tsiang, H.; Superti, F. Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Brief report. Arch. Virol., 1984, 81(3-4), 377-382.
164. Conti, C.; Superti, F.; Divizia, M.; Pana, A.; Orsi, N. Effect of inhibitors of cytoplasmic structures and functions on rabies virus infection in vitro. Comp. Immunol. Microbiol. Infect. Dis., 1990, 13(3), 137-146.
165. Bussereau, F.; Perrin, P. Cellular response to rabies virus infection. Comp. Immunol. Microbiol. Infect. Dis., 1982, 5(1-3), 49-59.
166. Lycke, E.; Tsiang, H. Rabies virus infection of cultured rat sensory neurons. J. Virol., 1987, 61(9), 2733-2741.
167. Lockhart, B.P.; Tsiang, H. Actin-independent maturation of rabies virus in neuronal cultures. J. Gen. Virol., 1991, 72(Pt 9), 2257-2261.
168. Tsiang, H. Evidence for an intraaxonal transport of fixed and street rabies virus. J. Neuropathol. Exp. Neurol., 1979, 38(3), 286-299.
169. Bulenga, G.; Heaney, T. Post-exposure local treatment of mice infected with rabies with two axonal flow inhibitors, colchicine and vinblastine. J. Gen. Virol., 1978, 39(2), 381-385.
170. Anderson, J.A.; Daly, F.T. Jr.; Kidd, J.C. Human rabies after antiserum and vaccine postexposure treatment. Case report and review. Ann. Intern. Med., 1966, 64(6), 1297-1302.
171. Dean, D.J.; Sherman, I. Potency of commercial rabies vaccine used in man. Public Health Rep., 1962, 77, 705-710.
172. Barroeta, M.; Atanasiu, P. [Inhibiting action of interferon on the development of rabes virion in cell culture]. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D, 1969, 269(14), 1353-5.
173. Depoux, R. [Fixed Rabies Virus and Interferon]. C.R. Hebd. Seances Acad. Sci., 1965, 260, 354-356.
174. Wiktor, T.J.; Postic, B.; Ho, M.; Koprowski, H. Role of interferon induction in the protective activity of rabies vaccines. J. Infect. Dis., 1972, 126(4), 408-418.
175. Marcovistz, R.; Germano, P.M.; Riviere, Y.; Tsiang, H.; Hovanessian, A.G. The effect of interferon treatment in rabies prophylaxis in immunocompetent, immunosuppressed, and immunodeficient mice. J. Interferon Res., 1987, 7(1), 17-27.
176. Postic, B.; Fenje, P. Effect of administered interferon on rabies in rabbits. Appl. Microbiol., 1971, 22(3), 428-431.
177. Vieuchange, J.; Chabaud, M.A.; Vialat, C. [Interference between vacciniavirus and street rabies virus]. C. R. Seances Soc. Biol. Fil., 1966, 160(12), 2278-2283.
178. Vieuchange, J.; Chabaud, M.A.; Vialat, C. [Interference between vaccine virus and fixed rabies virus]. Bull. Acad. Natl. Med., 1967, 151(1), 33-36.
179. Atanasiu, P.; Barroeta, M.; Tsiang, H.; Favre, S. [In vivo inhibition of rabies virus multiplication by an endogenous interferon]. Ann. Inst. Pasteur (Paris), 1970, 119(6), 767-777.
180. Vieuchange, J.; Fayaz, A.; de Lalun, E. [Interference between Newcastle disease virus and rabies virus in rabbits: utilization of this phenomenon in the prevention of experimental rabies]. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D, 1970, 271(8), 734-736.
181. Fayaz, A.; Afshar, A.; Bahmanyar, M. Interference between bovine parainfluenza 3 virus and a street strain of rabies virus in rabbits. Arch. Gesamte Virusforsch., 1970, 29(2), 159-162.
182. Soave, O.A. Influence of statolon-induced interferon on rabies virus infection in mice. Am. J. Vet. Res., 1968, 29(7), 1507-1508.
183. Hilfenhaus, J.; Karges, H.E.; Weinmann, E.; Barth, R. Effect of administered human interferon on experimental rabies in monkeys. Infect. Immun., 1975, 11(5), 1156-1158.
184. Hilfenhaus, J.; Weinmann, E.; Majer, M.; Barth, R.; Jaeger, O. Administration of human interferon to rabies virus-infected monkeys after exposure. J. Infect. Dis., 1977, 135(5), 846-849.
185. Bahmanyar, M.; Fayaz, A.; Vieuchange, J. [Presence of an active substance of the interferon type with respect to street rabies, in extracts of tissues infected with vaccine]. C. R. Seances Soc. Biol. Fil, 1967, 161(2), 255-258.
186. Vieuchange, J. [The action of an interferon regarding experimental rabies of the rabbit]. Bull. Acad. Natl. Med., 1969, 153(21), 374-378.
187. Fenje, P.; Postic, B. Protection of rabbits against experimental rabies of poly I-poly C. Nature, 1970, 226(5241), 171-172.
188. Fenje, P.; Postic, B. Prophylaxis of experimental rabies with the polyriboinosinic-polyribocytidylic acid complex. J. Infect. Dis., 1971, 123(4), 426-428.
189. Janis, B.; Habel, K. Rabies in rabbits and mice: protective effect of polyriboinosinic-polyribocytidylic acid. J. Infect. Dis., 1972, 125(4), 345-352.
190. Lin, H.X.; Gontier, C.; Saron, M.F.; Perrin, P. A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects. Arch. Virol., 1993, 131(3-4), 307-319.
191. Tazulakhova, E.B.; Parshina, O.V.; Guseva, T.S.; Ershov, F.I. Russian experience in screening, analysis, and clinical application of novel interferon inducers. J. Interferon Cytokine Res., 2001, 21(2), 65-73.
192. Harmon, M.W.; Janis, B.; Levy, H.B. Post-exposure prophylaxis of murine rabies with polyinosinic-polycytidylic acid and chlorite-oxidized amylose. Antimicro. Agents Chemother., 1974, 6(4), 507-511.
193. Harmon, M.W.; Janis, B. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines. J. Infect. Dis., 1975, 132(3), 241-249.
194. Baer, G.M.; Shaddock, J.H.; Moore, S.A.; Yager, P.A.; Baron, S.S.; Levy, H.B. Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J. Infect. Dis., 1977, 136(2), 286-291.
195. Wiktor, T.J.; Koprowski, H.; Mitchell, J.R.; Merigan, T.C. Role of interferon in prophylaxis of rabies after exposure. J. Infect. Dis., 1976, 133 (Suppl), A260-265.
196. Weinmann, E.; Majer, M.; Hilfenhaus, J. Intramuscular and/or intralumbar postexposure treatment of rabies virus-infected cynomolgus monkeys with human interferon. Infect. Immun., 1979, 24(1), 24-31.
197. Gourmelon, P.; Briet, D.; Court, L.; Tsiang, H. Electrophysiological and sleep alterations in experimental mouse rabies. Brain Res., 1986, 398(1), 128-140.
198. Koschel, K.; Halbach, M. Rabies virus infection selectively impairs membrane receptor functions in neuronal model cells. J. Gen. Virol., 1979, 42(3), 627-632.
199. Tsiang, H. Neuronal function impairment in rabies-infected rat brain. J. Gen. Virol., 1982, 61 (Pt 2), 277-281.
200. Lockhart, B.P.; Tordo, N.; Tsiang, H. Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob. Agents Chemother., 1992, 36(8), 1750-1755.
201. Lockhart, B.P.; Tsiang, H.; Ceccaldi, P.E.; Guillemer, S. Ketamine-mediated inhibition of rabies infection in vitro and in rat brain. Antivir. Chem. Chemother., 1991, 2(1), 9-15.
202. Tsiang, H.; Ceccaldi, P.E.; Ermine, A.; Lockhart, B.; Guillemer, S. Inhibition of rabies virus infection in cultured rat cortical neurons by an N-methyl-D-aspartate noncompetitive antagonist, MK-801. Antimicrob. Agents Chemother., 1991, 35(3), 572-574.
203. Olney, J.; Price, M.; Salles, K.S.; Labruyere, J.; Frierdich, G. MK-801 powerfully protects against N-methyl aspartate neurotoxicity. Eur. J. Pharmacol., 1987, 141(3), 357-361.
204. Chavez, J.H.; Leal, P.C.; Yunes, R.A.; Nunes, R.J.; Barardi, C.R.; Pinto, A.R.; Simoes, C.M.; Zanetti, C.R. Evaluation of antiviral activity of phenolic compounds and derivatives against rabies virus. Vet. Microbiol., 2006, 116(1-3), 53-59.
205. Weli, S.C.; Scott, C.A.; Ward, C.A.; Jackson, A.C. Rabies virus infection of primary neuronal cultures and adult mice: failure to demonstrate evidence of excitotoxicity. J. Virol., 2006, 80(20), 10270-10273.
206. Lenard, J.; Miller, D.K. Uncoating of enveloped viruses. Cell, 1982, 28(1), 5-6.
207. Schlegel, R.; Dickson, R.B.; Willingham, M.C.; Pastan, I.H. Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin. Proc. Natl. Acad. Sci. USA, 1982, 79(7), 2291-2295.
208. Superti, F.; Seganti, L.; Pana, A.; Orsi, N. Effect of amantadine on rhabdovirus infection. Drugs Exp. Clin. Res., 1985, 11(1), 69-74.
209. Glasgow, L.A.; Galasso, G.J. Isoprinosine: lack of antiviral activity in experimental model infections. J. Infect. Dis., 1972, 126(2), 162-169.
210. Hernandez-Jauregui, P.; Gonzalez-Vega, D.; Cruz-Lavin, E.; Hernandez-Baumgarten, E. In vitro effect of isoprinosine on rabies virus. Am. J. Vet. Res., 1980, 41(9), 1475-1478.
211. Enright, J.B.; Goggin, J.E.; Frye, F.L.; Franti, C.E.; Behymer, D.E. Effects of corticosteroids on rabies virus infections in various animal species. J. Am. Vet. Med. Assoc., 1970, 156(6), 765-769.
212. Enright, J.B.; Franti, C.E.; Frye, F.L.; Behymer, D.E. The effects of corticosteroids on rabies in mice. Can. J. Microbiol., 1970, 16(8), 667-675.
213. Tsiang, H.; Atanasiu, P.; Chermann, J.C.; Jasmin, C. Inhibition of rabies virus in vitro by the ammonium-5-tungsto-2-antimoniate. J. Gen. Virol., 1978, 40(3), 665-668.
214. Pepin, M.; Blancou, J. Ammonium-5-tungsto-2-antimoniate (HPA23) can prevent fox rabies. Arch. Virol., 1985, 83(3-4), 327-329.
215. Banic, S. Prevention of rabies by vitamin C. Nature, 1975, 258(5531), 153-154.
216. Madhusudana, S.N.; Shamsundar, R.; Seetharaman, S. In vitro inactivation of the rabies virus by ascorbic acid. Int. J. Infect. Dis., 2004, 8(1), 21-25.
217. Pons, M.W.; Preston, W.S. The in vivo inhibition by beta-phenylserine of rabies, myxoma, and vaccinia viruses. Virology, 1961, 15, 164-172.
218. Jackson, A.C.; Scott, C.A.; Owen, J.; Weli, S.C.; Rossiter, J.P. Therapy with minocycline aggravates experimental rabies in mice. J. Virol., 2007, 81(12), 6248-6253.
219. Danilov, L.L.; Maltsev, S.D.; Deyeva, A.V.; Narovlyansky, A.N.; Sanin, A.V.; Ozherelkov, S.V.; Pronin, A.V. Phosprenyl: a novel drug with antiviral and immunomodulatory activity. Arch. Immunol. Ther. Exp. (Warsz), 1996, 44(5-6), 395-400.
220. Smania, A., Jr.; Marques, C.J.; Smania, E.F.; Zanetti, C.R.; Carobrez, S.G.; Tramonte, R.; Loguercio-Leite, C. Toxicity and antiviral activity of cinnabarin obtained from Pycnoporus sanguineus (Fr.) Murr. Phytother. Res., 2003, 17(9), 1069-1072.
221. Kawai, A.; Fujita, K. Small red bean (azuki) sheds biologically active substances as a prerequisite step for germination, one of which displays the antiviral activity against the rabies virus infectivity and infections in culture. Microbiol. Immunol., 2007, 51(11), 1071-1079.
222. Muller, V.; Chavez, J.H.; Reginatto, F.H.; Zucolotto, S.M.; Niero, R.; Navarro, D.; Yunes, R.A.; Schenkel, E.P.; Barardi, C.R.; Zanetti, C.R.; Simoes, C.M. Evaluation of antiviral activity of South American plant extracts against herpes simplex virus type 1 and rabies virus. Phytother. Res., 2007, 21(10), 970-974.
223. Brandao, P.E.; Castilho, J.G.; Fahl, W.; Carnieli, P., Jr.; Oliveira Rde, N.; Macedo, C.I.; Carrieri, M.L.; Kotait, I. Short-interfering RNAs as antivirals against rabies. Braz. J. Infect. Dis., 2007, 11(2), 224-225.
224. Wunner, W.H.; Pallatroni, C.; Curtis, P.J. Selection of genetic inhibitors of rabies virus. Arch. Virol., 2004, 149(8), 1653-1662.
225. Israsena, N.; Supavonwong, P.; Ratanasetyuth, N.; Khawplod, P.; Hemachudha, T. Inhibition of rabies virus replication by multiple artificial microRNAs. Antiviral Res., 2009, 84(1), 76-83.
226. Real, E.; Rain, J.C.; Battaglia, V.; Jallet, C.; Perrin, P.; Tordo, N.; Chrisment, P.; D'Alayer, J.; Legrain, P.; Jacob, Y. Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides. J. Virol., 2004, 78(14), 7410-7417.
227. Castel, G.; Chteoui, M.; Caignard, G.; Prehaud, C.; Mehouas, S.; Real, E.; Jallet, C.; Jacob, Y.; Ruigrok, R.W.; Tordo, N. Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity. J. Virol., 2009, 83(20), 10808-10820.
228. Pietropaolo, V.; Seganti, L.; Marchetti, M.; Sinibaldi, L.; Orsi, N.; Nicoletti, R. Effect of natural and semisynthetic polymers on rabies virus infection in CER cells. Res. Virol., 1993, 144(2), 151-158.
229. Gode, G.R.; Raju, A.V.; Jayalakshmi, T.S.; Kaul, H.L.; Bhide, N.K. Intensive care in rabies therapy. Clinical observations. Lancet, 1976, 2(7975), 6-8.
230. Hattwick, M.A.; Weis, T.T.; Stechschulte, C.J.; Baer, G.M.; Gregg, M.B. Recovery from rabies. A case report. Ann. Intern. Med., 1972, 76(6), 931-942.
231. Porras, C.; Barboza, J.J.; Fuenzalida, E.; Adaros, H.L.; Oviedo, A.M.; Furst, J. Recovery from rabies in man. Ann. Intern. Med., 1976, 85(1), 44-48.
232. CDC Follow-up of rabies--New York. MMWR Morb. Mortal. Wkly Rep., 1977, 26(33), 249-250.
233. Alvarez, L.; Fajardo, R.; Lopez, E.; Pedroza, R.; Hemachudha, T.; Kamolvarin, N.; Cortes, G.; Baer, G.M. Partial recovery from rabies in a nine-year-old boy. Pediatr. Infect. Dis. J., 1994, 13(12), 1154-1155.
234. Madhusudana, S.N.; Nagaraj, D.; Uday, M.; Ratnavalli, E.; Kumar, M.V. Partial recovery from rabies in a six-year-old girl. Int. J. Infect. Dis., 2002, 6(1), 85-86.
235. Presumptive abortive human rabies - Texas, 2009. MMWR Morb. Mortal. Wkly Rep., 2010, 59(7), 185-190.
236. Merigan, T.C.; Baer, G.M.; Winkler, W.G.; Bernard, K.W.; Gibert, C.G.; Chany, C.; Veronesi, R. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann. Neurol., 1984, 16(1), 82-87.
237. Parham, G.L. Rabies in the United States, 1981. Morb. Mortal. Wkly Rep. Surveill. Summ., 1983, 32(1), 33SS-37SS.
238. CDC Imported human rabies. MMWR Morb. Mortal. Wkly Rep., 1983, 32(6), 78-80, 85-86.
239. Warrell, M.J.; White, N.J.; Looareesuwan, S.; Phillips, R.E.; Suntharasamai, P.; Chanthavanich, P.; Riganti, M.; Fisher-Hoch, S.P.; Nicholson, K.G.; Manatsathit, S.; et al. Failure of interferon alfa and tribavirin in rabies encephalitis. Br. Med. J., 1989, 299(6703), 830-833.
240. Gode, G.R.; Saksena, R.; Batra, R.K.; Kalia, P.K.; Bhide, N.K. Treatment of 54 clinically diagnosed rabies patients with two survivals. Indian J. Med. Res., 1988, 88, 564-566.
241. Webster, W.A.; Casey, G.A.; Charlton, K.M.; Sayson, R.C.; McLaughlin, B.; Noble, M.A. A case of human rabies in western Canada. Can. J. Public Health, 1987, 78(6), 412-413.
242. Dolman, C.L.; Charlton, K.M. Massive necrosis of the brain in rabies. Can. J. Neurol. Sci., 1987, 14(2), 162-165.
243. CDC Human rabies--Texas. MMWR Morb. Mortal. Wkly Rep., 1984, 33(33), 469-470.
244. Kureishi, A.; Xu, L.Z.; Wu, H.; Stiver, H.G. Rabies in China: recommendations for control. Bull. World Health Organ., 1992, 70(4), 443-450.
245. Anderson, L.J.; Nicholson, K.G.; Tauxe, R.V.; Winkler, W.G. Human rabies in the United States, 1960 to 1979: epidemiology, diagnosis, and prevention. Ann. Intern. Med., 1984, 100(5), 728-735.
246. Hemachudha, T.; Sunsaneewitayakul, B.; Mitrabhakdi, E.; Suankratay, C.; Laothamathas, J.; Wacharapluesadee, S.; Khawplod, P.; Wilde, H. Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies. Int. J. Infect. Dis., 2003, 7(1), 76-77.
247. Maton, P.N.; Pollard, J.D.; Davis, J.N. Human rabies encephalomyelitis. Br. Med. J., 1976, 1(6017), 1038-1040.
248. Cohen, S.L.; Gardner, S.; Lanyi, C.; McDonald, J.R.; Ree, H.; Southorn, P.A.; Woodruff, A.W. A case of rabies in man: some problems in diagnosis and management. Br. Med. J., 1976, 1(6017), 1041-1042.
249. Emmons, R.W.; Leonard, L.L.; DeGenaro, F., Jr.; Protas, E.S.; Bazeley, P.L.; Giammona, S.T.; Sturckow, K. A case of human rabies with prolonged survival. Intervirology, 1973, 1(1), 60-72.
250. Harris, D.L. A clinical report of seven cases of hydrophobia. JAMA, 1913, 61(17), 1511-1514.
251. Jackson, A.C.; Warrell, M.J.; Rupprecht, C.E.; Ertl, H.C.; Dietzschold, B.; O'Reilly, M.; Leach, R.P.; Fu, Z.F.; Wunner, W.H.; Bleck, T.P.; Wilde, H. Management of rabies in humans. Clin. Infect. Dis., 2003, 36(1), 60-63.
252. CDC Human death associated with bat rabies--California, 2003. MMWR Morb. Mortal. Wkly Rep., 2004, 53(2), 33-35.
253. Willoughby, R.E., Jr.; Tieves, K.S.; Hoffman, G.M.; Ghanayem, N.S.; Amlie-Lefond, C.M.; Schwabe, M.J.; Chusid, M.J.; Rupprecht, C.E. Survival after treatment of rabies with induction of coma. N. Engl. J. Med., 2005, 352(24), 2508-2514.
254. Bhatt, D.R.; Hattwick, M.A.; Gerdsen, R.; Emmons, R.W.; Johnson, H.N. Human rabies. Diagnosis, complications, and management. Am. J. Dis. Child, 1974, 127(6), 862-869.
255. Rubin, R.H.; Sullivan, L.; Summers, R.; Gregg, M.B.; Sikes, R.K. A case of human rabies in Kansas: epidemiologic, clinical, and laboratory considerations. J. Infect. Dis., 1970, 122(4), 318-322.
256. Hu, W.T.; Willoughby, R.E. Jr.; Dhonau, H.; Mack, K.J. Long-term follow-up after treatment of rabies by induction of coma. N. Engl. J. Med., 2007, 357(9), 945-946.
257. Wilde, H.; Hemachudha, T.; Jackson, A.C. Viewpoint: Management of human rabies. Trans. R. Soc. Trop. Med. Hyg., 2008, 102(10), 979-982.
258. Jackson, A.C. Recovery from rabies. N. Engl. J. Med., 2005, 352(24), 2549-2550.
259. Medical College of Wisconsin. Pediatric: Infectious Diseases, http://www.mcw.edu/Pediatrics/InfectiousDiseases/Rabies.htm. (Accessed October 5, 2010).
260. Hemachudha, T.; Sunsaneewitayakul, B.; Desudchit, T.; Suankratay, C.; Sittipunt, C.; Wacharapluesadee, S.; Khawplod, P.; Wilde, H.; Jackson, A.C. Failure of therapeutic coma and ketamine for therapy of human rabies. J. Neurovirol., 2006, 12(5), 407-409.
261. ProMED-mail Rabies, human - USA (TX). ProMED-mail 2006, 13 May(20060513.1360), http://www.promedmail.org. Accessed 18 May 2006.
262. CDC Human rabies--Indiana and California, 2006. MMWR Morb. Mortal. Wkly Rep., 2007, 56(15), 361-365.
263. Schmiedel, S.; Panning, M.; Lohse, A.; Kreymann, K.G.; Gerloff, C.; Burchard, G.; Drosten, C. Case report on fatal human rabies infection in Hamburg, Germany, March 2007. Euro. Surveill., 2007, 12(5), E0705315.
264. van Thiel, P.P.; de Bie, R.M.; Eftimov, F.; Tepaske, R.; Zaaijer, H.L.; van Doornum, G.J.; Schutten, M.; Osterhaus, A.D.; Majoie, C.B.; Aronica, E.; Fehlner-Gardiner, C.; Wandeler, A.I.; Kager, P.A. Fatal human rabies due to duvenhage virus from a bat in Kenya: Failure of treatment with coma-induction, ketamine, and antiviral drugs. PLoS Negl. Trop. Dis., 2009, 3(7), e428.
265. van Thiel, P.P.; van den Hoek, J.A.; Eftimov, F.; Tepaske, R.; Zaaijer, H.J.; Spanjaard, L.; de Boer, H.E.; van Doornum, G.J.; Schutten, M.; Osterhaus, A.; Kager, P.A. Fatal case of human rabies (Duvenhage virus) from a bat in Kenya: The Netherlands, December 2007. Euro. Surveill., 2008, 13(2).
266. Rubin, J.; David, D.; Willoughby, R.E., Jr.; Rupprecht, C.E.; Garcia, C.; Guarda, D.C.; Zohar, Z.; Stamler, A. Applying the Milwaukee protocol to treat canine rabies in Equatorial Guinea. Scand. J. Infect. Dis., 2009, 41(5), 372-375.
267. McDermid, R.C.; Saxinger, L.; Lee, B.; Johnstone, J.; Gibney, R.T.; Johnson, M.; Bagshaw, S.M. Human rabies encephalitis following bat exposure: failure of therapeutic coma. CMAJ, 2008, 178(5), 557-561.
268. Hunter, M.; Johnson, N.; Hedderwick, S.; McCaughey, C.; Lowry, K.; McConville, J.; Herron, B.; McQuaid, S.; Marston, D.; Goddard, T.; Harkess, G.; Goharriz, H.; Voller, K.; Solomon, T.; Willoughby, R.E.; Fooks, A.R. Immunovirological correlates in human rabies treated with therapeutic coma. J. Med. Virol., 2010, 82(7), 1255-1265.
269. ProMED-mail Rabies, human, bat - Brazil (03): Goias. ProMED-mail 2008, 24 December(20081224.4057), http://www.promed-mail.org. Accessed 24 December 2008.
270. ProMED-mail Rabies - Brazil: (GO). ProMED-mail 2009, 28 January (20090128.0394), http://www.promedmail.org. Accessed 28 January 2008.
271. ProMED-mail Rabies, human survival, bat - Brazil: (Pernambuco). ProMED-mail 2008, 15 November(20081114.3599),1 http://www.promedmail.org. Accessed 15 November 2008.
272. ProMED-mail Rabies, human survival, bat - Brazil (02): (Pernambuco). ProMED-mail 2008, 22 November (20081122. 3689), http://www.promedmail.org. Accessed 22 November 2008.
273. ProMED-mail Rabies - Brazil (03): (PE), recovery. ProMED-mail 2009, 14 February(20090214.0638), http://www.promed-mail.org. Accessed 14 February 2009.
274. ProMED-mail PRO/AH/EDR> Rabies - Brazil (04): (PE), recovery. ProMED-mail 2009, 20 September(20090919.3292), http://www.promedmail.org. Accessed 20 September 2009.
275. Vieuchange, J.; Fayaz, A. [Attempt at prevention of experimental rabies in the rabbit by means of a tissue extract of the type interferon injected during the incubation period]. C. R. Acad. Sci. Hebd. Seances Acad. Sci. D., 1969, 268(6), 991-993.
276. Ho, M.; Nash, C.; Morgan, C.W.; Armstrong, J.A.; Carroll, R.G.; Postic, B. Interferon administered in the cerebrospinal space and its effect on rabies in rabbits. Infect. Immun., 1974, 9(2), 286-293.